查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2001249

全球胜肽類藥物複合體市場：市場機會、藥物銷售、專利、定價、劑量、專有技術和臨床試驗展望（2031年）

Global Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031
出版日期: | 出版商: KuicK Research | 英文 160 Pages | 商品交期: 最快1-2個工作天內

價格

全球胜肽類藥物複合體市場的商業機會、藥物銷售、專利、定價、劑量、專有技術和臨床試驗展望（2031年）報告的研究結果及亮點：

  • 全球胜肽類藥物複合體市場機會：到2031年將超過15億美元
  • 2021年至2025年全球胜肽類藥物複合體市場成長：年複合成長率超過14%
  • 深入了解已通過核准肽類藥物複合體的劑量、定價和銷售情況。
  • 全面深入了解臨床試驗中的胜肽藥物複合體：超過50種胜肽複合體
  • 依公司、國家、適應症和階段分析全球胜肽類藥物複合體臨床試驗。
  • 肽類藥物複合體開發中專有技術的深入剖析：18 項技術

肽類藥物複合體的必要性及本報告的意義

胜肽藥物複合體（PDCs）正日益成為最有前景的新興治療方法之一，能夠克服傳統藥物遞送系統的一些主要限制。肽-藥物複合體可用於解決全身毒性、選擇性不足、組織滲透性差、抗藥性等問題。

肽-藥物複合體因其能夠透過精準標靶化改善患者的臨床療效，尤其是在癌症治療領域，而備受關注。然而，肽-藥物複合體的潛力不僅限於癌症治療；它們還可用於治療其他疾病，例如感染疾病、發炎和代謝紊亂，使其成為廣泛應用的藥物遞送系統。

截至2026年3月，全球胜肽藥物複合體市場仍處於早期階段，但發展迅速。目前已通過核准的治療方法有限，且僅有概念驗證（PoC）證明了其臨床和商業性可行性。同時，在胜肽化學和藥物偶聯技術創新的推動下，大量肽-藥物複合體研發和商業化過程中。

本報告整合了科學、臨床、技術和商業性等多個方面，全面展現了全球胜肽類藥物複合體市場的概況。目的是幫助製藥公司和投資者了解這個新興且不斷發展的治療領域的趨勢和機會。

報告中包含對臨床試驗的深入分析

臨床開發是肽類藥物複合體的主要成長要素，其多階段研發管線穩步擴展，反映出人們對其治療潛力的信心日益增強。腫瘤學仍然是主要研究方向，肽類藥物複合體靶向腫瘤中過度表達的受體，實現精準給藥，提高安全性和療效。後期臨床試驗中令人鼓舞的結果進一步凸顯了這項潛力。除癌症外，研究範圍擴展到感染疾病疾病和發炎性疾病，胜肽類藥物複合體目的是選擇性地靶向感染或活化的細胞，增強治療效果，同時最大限度地減少全身暴露和相關副作用。

本報告對各階段的臨床試驗進行了詳細評估，涵蓋從早期探索性研究到後期驗證性試驗的各個方面。報告分析了研究設計、患者選擇、給藥策略和聯合治療等關鍵要素，目的是識別新興趨勢和未來發展方向。多種候選藥物進入後期研發階段，顯示此類治療藥物正日趨成熟。

著重胜肽類藥物複合體研發的主要企業

肽類藥物複合體市場的競爭格局是由老牌製藥公司和創新生物技術公司之間的合作所推動的。Novartis等主要企業發揮了先鋒作用，尤其是在放射性標記肽療法和標靶癌症治療方面取得了顯著進展，為該領域樹立了重要的標竿。同樣，Oncopeptides公司也為骨髓惡性腫瘤肽治療方法發展做出了貢獻。

同時，新興的生物技術產業正加速胜肽類藥物複合體（PDM）產業的發展。 Bicycle Therapeutics、Cybrexa Therapeutics和PepGen等公司正積極致力於開發新型胜肽平台和連接子技術，並改進靶向藥物遞送平台。這些措施不僅增強了PDM產業的實力，也拓展了PDM的應用範圍，使其能夠用於治療包括非癌症疾病在內的多種疾病。

肽類藥物複合體產業的競爭格局是由製藥和生物技術兩大產業共同努力塑造的。這兩個產業正致力於創新和策略擴張，尤其是在研發領域，以期在這個新興產業中奠定堅實的基礎。

技術平台、合作夥伴關係和協議

技術創新是胜肽藥物複合體開發的關鍵要素，胜肽設計、偶聯化學和連接子技術的進步顯著提高了藥物複合體的穩定性、特異性和療效。胜肽藥物複合體技術的新方法包括增強結合親和性、最佳化藥物控釋和改善藥物動力學。肽-藥物複合體的一項關鍵創新是使用「智慧連接子」，它能夠回應酶和pH等觸發因素釋放藥物，同時保持藥物在循環系統中的穩定性。另一項創新是胜肽的環化和非天然胺基酸的使用，這透過增強胜肽對酵素分解的抵抗力來提高其穩定性。

影響胜肽類藥物複合體技術發展的另一個重要因素是合作研究和策略夥伴關係。透過跨領域合作，企業可以提高研發效率並增強技術能力。此外，隨著該領域高度協作的創新進程不斷推進，授權協議也日益普遍。

一份概述胜肽藥物複合體片段未來發展方向的報告。

技術創新在胜肽藥物複合體的開發中發揮核心作用，胜肽設計、偶聯化學和連接子技術的進步顯著提高了藥物複合體的穩定性、特異性和治療效果。現代策略著重於增強結合親和性、最佳化藥物控釋、改善藥物動力學。一項關鍵創新是使用「智慧連接子」，這種連接子能夠回應酶或pH值變化等觸發因素釋放活性成分，同時保持藥物在循環系統中的穩定性。此外，肽環化和非天然氨基酸的引進增強了藥物複合體對酶分解的抵抗力，並提高了整體穩定性。

總之，在加大投資、臨床檢驗和技術創新的支持下，肽-藥物複合體有望在下一代標靶治療的開發中發揮重要作用，用於治療多種疾病。

目錄

第1章 調查方法

第2章 胜肽藥物複合體概述

  • 概述
  • 歷史與演變
  • 肽類藥物複合體與抗體藥物複合體

第3章 胜肽藥物複合體 - 結構組成與作用機制

  • 成分
  • 作用機制

第4章 依適應症的分類胜肽藥物複合體的研究與發展趨勢

  • 癌症
  • 微生物感染疾病
  • 其他

第5章 全球胜肽類藥物複合體市場展望

  • 最新臨床和市場趨勢
  • 未來市場展望及機會
  • 肽類藥物複合體開發中的專有技術和方法

第6章 全球胜肽類藥物複合體調查及市場趨勢（依地區）

  • 美國
  • 中國
  • 日本
  • 歐洲
  • 韓國

第7章 Lutathera - 臨床與商業性見解

  • 概述、可用性和專利資訊
  • 劑量和價格分析
  • 銷售分析

第8章 Pepaxto/Pepaxti - 臨床和商業性見解

  • 概述和可用性
  • 劑量分析
  • 銷售分析

第9章 胜肽類藥物複合體全球臨床開發平臺概述

  • 階段
  • 公司
  • 國家
  • 適應症
  • 優先事項

第10章 胜肽類藥物複合體臨床試驗的全球概況（依公司、國家、適應症和階段）

  • 研究
  • 臨床前
  • 第一期
  • 第一/二期
  • 第二期
  • 第三期
  • 預註冊

第11章 市售胜肽類藥物複合體的臨床研究結果

第12章 競爭格局

  • Angiochem
  • Avacta
  • Bicycle Therapeutics
  • Cybrexa Therapeutics
  • ITM Solucin
  • Novartis
  • Oncopeptides
  • PepGen Corporation
  • Soricimed Biopharma
  • Theratechnologies

Global Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031 Report Findings & Highlights:

  • Global Peptide Drug Conjugate Market Opportunity: > USD 1.50 Billion By 2031
  • Global Peptide Drug Conjugate Market Growth 2021 -2025: > 14% CAGR
  • Approved Peptide Drug Conjugates Dosage, Pricing & Sales Insight
  • Comprehensive Insight On Peptide Drug Conjugate In Clinical Trials: > 50 Peptide Conjugates
  • Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
  • Insight On Peptide Drug Conjugate Development Proprietary Technologies: 18 Technologies

Need For Peptide Drug Conjugates & Why This Report?

Peptide Drug Conjugates (PDCs) are increasingly proving to be one of the most promising emerging therapeutics that can address some of the major limitations associated with conventional drug delivery systems. Peptide Drug Conjugates can be used to overcome issues such as systemic toxicity, lack of selectivity, poor tissue penetration, and development of drug resistance.

Significant interest has been generated in Peptide Drug Conjugates, especially for cancer therapy, where precise targeting can improve clinical outcomes for patients. However, potential for Peptide Drug Conjugates is not limited to cancer therapy, but can be used to treat other diseases such as infections, inflammation, and metabolic diseases, making them a broad-spectrum drug delivery system.

As of March 2026, the global Peptide Drug Conjugate market remains in an early but rapidly evolving phase, with a limited number of approved therapies providing proof-of-concept for clinical and commercial viability. At the same time, there is a strong pipeline of Peptide Drug Conjugates that are being developed and commercialized based on innovations in peptide chemistry and drug conjugation.

This report presents an all-inclusive view of the global Peptide Drug Conjugate market, integrating scientific, clinical, technical, and commercial aspects. It is designed to help pharmaceutical companies and investors to understand the developments and emerging opportunities in this new and expanding area of therapeutics.

Clinical Trials Insight Included In Report

Clinical development is a key growth driver for Peptide Drug Conjugates, with a steadily expanding pipeline across multiple stages reflecting increasing confidence in their therapeutic potential. Oncology remains the primary focus, where Peptide Drug Conjugates target overexpressed tumor receptors to enable precise drug delivery with improved safety and efficacy. Encouraging outcomes from late-stage trials further support their promise. Beyond cancer, research is extending into infectious and inflammatory diseases, where Peptide Drug Conjugates are designed to selectively target infected or activated cells, enhancing treatment effectiveness while minimizing systemic exposure and associated side effects.

The report provides a detailed assessment of clinical trials across all phases, including early-stage exploratory studies and late-stage confirmatory trials. Key aspects such as study design, patient selection, dosing strategies, and combination approaches have been analyzed to identify emerging trends and future development pathways. The progression of multiple candidates into advanced stages of development highlights the increasing maturity of this therapeutic class.

Major Companies Active In R&D Of Peptide Drug Conjugates

The competitive landscape of the Peptide Drug Conjugate market is driven by the combined efforts of established pharmaceutical companies and innovative biotechnology firms. Major players such as Novartis have played a pioneering role, particularly through advancements in radiolabeled peptide therapeutics and targeted oncology treatments, setting important benchmarks for the field. Similarly, Oncopeptides has contributed to the development of peptide-based therapies in hematological malignancies.

On the other hand, the emerging biotechnology industry is accelerating the progress of the Peptide Drug Conjugate industry. Companies like Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen are actively involved in the development of novel peptide platforms, linker technologies, and improving targeted drug delivery platforms, which are not only strengthening the Peptide Drug Conjugate industry but also expanding the scope of Peptide Drug Conjugates for the treatment of a wide range of diseases, including those other than cancer.

The competitive environment of the Peptide Drug Conjugate industry is shaped by the cumulative efforts of the pharmaceutical and biotechnology industry, which is focused on innovation and strategic expansion, especially in the form of research and development to consolidate a strong footing in this emerging industry.

Technology Platforms, Collaborations & Agreements

Technological innovation is an integral part of Peptide Drug Conjugate development, as advancements in peptide design, conjugate chemistry, and linker technology improve stability, specificity, and efficacy. New approaches in Peptide Drug Conjugate technology involve improvement in binding affinity, optimization of controlled drug release, and pharmacokinetics. The major technological innovation in Peptide Drug Conjugate is the use of smart linkers that remain stable in circulation but can release drugs in response to triggers such as enzymes or pH. Another innovation is peptide cyclization and the use of non-natural amino acids to improve stability by resisting enzymatic degradation.

Another factor that is significantly impacting Peptide Drug Conjugate technology is collaborations and strategic partnerships. By leveraging partnerships in various fields of study, companies are able to improve efficiency in their research and increase their technological capabilities. Licensing agreements are also becoming increasingly prevalent in this field as it is a highly collaborative innovation process.

Report Indicating Future Direction Of Peptide Drug Conjugate Segment

Technological innovation is central to Peptide Drug Conjugate development, with advances in peptide design, conjugation chemistry, and linker technologies enhancing stability, specificity, and therapeutic performance. Modern strategies focus on improving binding affinity, optimizing controlled drug release, and refining pharmacokinetics. A key innovation is the use of smart linkers that remain stable in circulation but release payloads in response to triggers like enzymes or pH changes. Additionally, peptide cyclization and incorporation of non-natural amino acids improve resistance to enzymatic degradation and enhance overall stability.

In conclusion, peptide drug conjugates, backed by increasing investment, clinical validation, and technological innovation, are likely to play a major role in the development of the next generation of targeted therapies for a wide range of diseases.

Table of Contents

1. Research Methodology

2. Introduction To Peptide Drug Conjugates

  • 2.1 Overview
  • 2.2 History & Evolution
  • 2.3 Peptide Drug Conjugates v/s Antibody Drug Conjugates

3. Peptide Drug Conjugates - Structural Components & Mechanism of Action

  • 3.1 Components
  • 3.2 Mechanism of Action

4. Peptide Drug Conjugates Research & Development Trends By Indication

  • 4.1 Cancer
  • 4.2 Microbial Infections
  • 4.3 Others

5. Global Peptide Drug Conjugates Market Outlook

  • 5.1 Current Clinical & Market Trends
  • 5.2 Future Market Outlook & Opportunities
  • 5.3 Peptide Drug Conjugate Development Proprietary Technologies & Methodologies

6. Global Peptide Drug Conjugates Research & Market Trends By Region

  • 6.1 US
  • 6.2 China
  • 6.3 Japan
  • 6.4 Europe
  • 6.5 South Korea

7. Lutathera - Clinical & Commercial Insight

  • 7.1 Overview, Availability & Patent Insight
  • 7.2 Dosage & Price Analysis
  • 7.3 Sales Analysis

8. Pepaxto/Pepaxti - Clinical & Commercial Insight

  • 8.1 Overview & Availability
  • 8.2 Dosage Analysis
  • 8.3 Sales Analysis

9. Global Peptide Drug Conjugates Clinical Pipeline Overview

  • 9.1 By Phase
  • 9.2 By Company
  • 9.3 By Country
  • 9.4 By Indication
  • 9.5 By Priority Status

10. Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase-I
  • 10.4 Phase-I/II
  • 10.5 Phase-II
  • 10.6 Phase-III
  • 10.7 Preregistration

11. Marketed Peptide Drug Conjugates Clinical Insight

12. Competitive Landscape

  • 12.1 Angiochem
  • 12.2 Avacta
  • 12.3 Bicycle Therapeutics
  • 12.4 Cybrexa Therapeutics
  • 12.5 ITM Solucin
  • 12.6 Novartis
  • 12.7 Oncopeptides
  • 12.8 PepGen Corporation
  • 12.9 Soricimed Biopharma
  • 12.10 Theratechnologies

List of Figures

  • Figure 2-1: Timeline Of Key Events In Development Of Peptide Drug Conjugates
  • Figure 3-1: Peptide Drug Conjugates - Components
  • Figure 3-2: Peptide Drug Conjugate - Mechanism Of Action
  • Figure 4-1: Approved Peptide Drug Conjugates
  • Figure 4-2: TH1902-CTR-0001 Phase I (NCT04706962) Study - Initiation & Completion Year
  • Figure 4-3: CBX-12-101 Phase I/II (NCT04902872) Study - Initiation & Completion Year
  • Figure 4-4: CBX-12-201 Phase II (NCT06315491) Study - Initiation & Completion Year
  • Figure 4-5: NCI-2022-11034 Phase I (NCT05691517) Study - Initiation & Completion Year
  • Figure 4-6: Duravelo-1 Phase I/II (NCT04561362) Study - Initiation & Completion Year
  • Figure 4-7: Duravelo-2 Phase II/III (NCT06225596) Study - Initiation & Completion Year
  • Figure 4-8: BT5528-100 Phase I/II (NCT04180371) Study - Initiation & Completion Year
  • Figure 4-9: BT5528-201 Phase II (NCT07450859) Study - Initiation & Completion Year
  • Figure 4-10: ALS-6000-101 Phase I (NCT04969835) Study - Initiation & Completion Year
  • Figure 4-11: PQ203-001 Phase I (NCT07190469) Study - Initiation & Completion Year
  • Figure 4-12: Rational Design Strategy For Anti-Infective PDCs
  • Figure 5-1: Global - Peptide drug Conjugates Market (US$ Million), 2018-2025
  • Figure 5-2: Global - Peptide drug Conjugates Market (US$ Million), 2026-2031
  • Figure 5-3: Potential Future Directions in Peptide-Drug Conjugate Development
  • Figure 5-4: alphalex Platform - Cybrexa
  • Figure 5-5: Decoy Platform - Candidate Life Cycle
  • Figure 5-6: Decoy Platform - Modular Peptide Engineering & Conjugation Chemistry
  • Figure 5-7: Decoy Platform - Features
  • Figure 5-8: EDO Platform - Drug Structure
  • Figure 5-9: OncoPDCs - Excellamol
  • Figure 5-10: PDPS Platform - PeptiDream
  • Figure 5-11: Rational Design Based Drug Discovery - Mainline Biosciences
  • Figure 5-12: pre|CISION(R) Platform - Generations & Features
  • Figure 5-13: PIP - Mechanism Of Action
  • Figure 5-14: PIP Platform - TwoStep Toolbox
  • Figure 5-15: Peptide - Advantages
  • Figure 5-16: SORT1+ Technology - PDC Structure
  • Figure 5-17: MPD-1 - Mechanism of Action
  • Figure 5-18: Bi-XDC Technology - Coherent Biopharma
  • Figure 5-19: NIPEP-TPP - NIBEC
  • Figure 7-1: Lutathera - Approval Year By Region
  • Figure 7-2: Lutathera - Patent Filing & Expiration Year
  • Figure 7-3: Global - Lutathera Sales (US$ Million), 202021-2025
  • Figure 7-4: Global - Lutathera Quarterly Sales (US$ Million), 2025
  • Figure 7-5: Regional - Lutathera Sales (US$ Million), 2025
  • Figure 7-6: Regional - Lutathera Sales (US$ Million), 2025
  • Figure 7-7: US - Lutathera Sales (US$ Million), 2023-2025
  • Figure 7-8: US - Lutathera Quarterly Sales (US$ Million), 2025
  • Figure 7-9: ROW - Lutathera Sales (US$ Million), 2023-2025
  • Figure 7-10: ROW - Lutathera Quarterly Sales (US$ Million), 2025
  • Figure 8-1: Pepaxto/Pepaxti - Approval Year By Region
  • Figure 8-2: Pepaxti - Patent Filing & Expiration Year
  • Figure 8-3: Europe - Pepaxti Sales (US$ Million), 2021-2025
  • Figure 9-1: Global - Peptide Drug Conjugate Clinical Pipeline By Phase (Number of Drugs), 2026 Till 2031
  • Figure 9-2: Global - Peptide Drug Conjugate Clinical Pipeline By Company (Number of Drugs), 2026 Till 2031
  • Figure 9-3: Global - Peptide Drug Conjugate Clinical Pipeline By Country (Number of Drugs), 2026 Till 2031
  • Figure 9-4: Global - Peptide Drug Conjugate Clinical Pipeline By Indication (Number of Drugs), 2026 Till 2031
  • Figure 9-5: Global - Peptide Drug Conjugate Clinical Pipeline By Priority Status (Number of Drugs), 2026 Till 2031

List of Tables

  • Table 2-1: Antibody Drug Conjugates v/s Peptide Drug Conjugates
  • Table 7-1: Lutathera - Recommended Amino Acid Solution Dosing
  • Table 7-2: Lutathera - Recommended Dosage Modifications For Adverse Reactions
  • Table 8-1: Pepaxti - Recommended Dose Reduction for Adverse Reactions
  • Table 8-2: Pepaxti - Recommended Dose Modifications for Adverse Reactions